You are here: Industry Insights > LEO Pharma

News List

FDA Approves Adbry drugs
January 05, 2022
FDA Approves Adbry (tralokinumab-ldrm) for Adults with Moderate-to-Severe Atopic Dermatitis
LEO Pharma and X-Chem Enter Into Discovery Research Agreement firstwordpharma
July 08, 2021
LEO Pharma A/S, a global leader in medical dermatology and X-Chem, Inc., the global leader in DNA-encoded library (DEL) driven discovery solutions, announced today that they have entered into a research collaboration and license agreement.
LEO Pharma announces European Commission approval of Adtralza (tralokinumab) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis firstwordpharma
June 23, 2021
LEO Pharma A/S today announced that the European Commission (EC) has approved Adtralza® (tralokinumab) for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.
LEO Pharma divests four medicines to Cheplapharm for $357m pharmaceutical-technology
September 01, 2020
Danish medical dermatology company LEO Pharma has divested a portfolio of four non-core medicines to German pharmaceutical firm Cheplapharm for €300m ($357m).
Leo Pharma’s tralokinumab meets key endpoints in phase 3 atopic dermatitis trials pharmaceutical-business-review
December 16, 2019
Danish medical dermatology firm Leo Pharma announced that its tralokinumab has achieved all primary and secondary endpoints in three phase 3 studies for the treatment of adults ...
LEO Pharma completes the acquisition of Bayer’s dermatology business biospectrumasia
July 04, 2019
LEO Pharma has now acquired the global product rights for Bayer's global prescription dermatology business with the exception of Afghanistan and Pakistan
LEO Pharma Completes Acquisition of Bayer’s Prescription Dermatology Business americanpharmaceuticalreview
July 03, 2019
LEO Pharma and Bayer announced the achievement of the relevant closing conditions to allow the transfer of Bayer’s global prescription dermatology business to LEO Pharma.
LEO Pharma appoints Catherine Mazzacco as new CEO biospectrumasia
June 05, 2019
LEO Pharma, a leader in medical dermatology has announced that Gitte Aabo will step down as President and CEO after 27 years in the company, 11 of these as CEO. The Board of Directors has appointed Catherine Mazzacco as new President and CEO effective Aug
LEO Pharma and Elektrofi Expand Partnership to Co-Develop New Antibodies with the Aim of Achieving Improvements in Drug Delivery within Dermatology firstwordpharma
April 10, 2019
BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology and Elektrofi, a Boston- based biotechnology company focused on drug formulation and delivery innovations...
LEO Pharma Chooses Veeva Development Cloud to Accelerate Drug Development pharmafocusasia
March 28, 2019
Veeva Systems today announced that LEO Pharma, an international leader in medical dermatology, has selected Veeva Development Cloud applications to help boost process end-to-end business on all product development.

Previous page 1 2 3 Next page